PLGA-PAA copolymers: Their size and structure influenced drug delivery applications
15th World Medical Nanotechnology Congress
October 18-19, 2017 Osaka, Japan

Elham Ahmadi, Mohammad Rahmati-Yamchi and Roya Salehi

Tabriz University of Medical Sciences, Iran

Scientific Tracks Abstracts: J Nanomed Nanotechnol

Abstract:

Statement of the Problem: The need for high cellular drug uptake and reduce the adverse effects of chemotherapeutic drugs obligate us to design and prepare a suitable nano-carrier. Poly (lactide-co-glycolic acid) PLGA is one of the most well used polymer for the development of biocompatible nanoparticles. Purpose: The purpose of the study is to prepare the PLGA-PAA (Poly-lactide-co-glycolide)-(poly acrylic acid) co-polymer which is the first new developed biocompatible nanocarrier until now. We co-encapsulated hydrophilic doxorubicin and hydrophilic hydroxytyrosol in PLGA-PAA biocompatible nanocapsules. Methodology & Theoretical Orientation: We synthesized the poly (acrylic acid) (PAA) polymer by radical polymerization method in the presence of dry tetrahydrofuran as solvent of the reaction. Then the PLGA-PAA copolymer was synthesized by ring opening polymerization method in the presence of stannous Octanoate (snoct2) as catalyst of the reaction. An oil-inwater emulsion process was utilized for the encapsulation of hydrophilic doxorubicin and hydroxytyrosol. Findings: FTIR confirmed the PAA and PLGA-PAA copolymer formation is correct. HNMR, CNMR also approved it. The size of PLGA-PAA nanoparticles is measured 24 nm by DLS technique and a spherical particle with an average diameter of 16 nm is determined by SEM technique. The amount of drug loading and unloading is computed. Conclusion & Significance: PLGA-PAA co-polymer was found to be a promising co-polymer for the preparation of nanoparticles with small size distribution and relatively high drug loading. Formulation of functionalized PLGA-PAA nanoparticles leads to enhance the high drug loading efficiency of hydrophilic drugs.

Biography :

Elham Ahmadi is currently pursuing her Masters in Medical Biotechnology at Tabriz University of Medical Sciences and completed Bachelor’s degree in Cellular and Molecular Biology from Azarbijan Shahid Madani University, Iran. She is currently working on a project of nanotechnology based drug delivery for anti-cancer targeting and treatment.